Trimetazidine as an Adjunct to Enhance Clopidogrel Response.
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
Hypothesis:
Trimetazidine improves Clopidogrel response in patients.
• The investigators postulate that the inhibition of platelet aggregation in response to
Clopidogrel may be accentuated by Trimetazidine, i.e. Trimetazidine enhances Clopidogrel
response.
Null Hypothesis:
There is no difference in Clopidogrel response in patients with stable coronary artery
disease with adjunctive Trimetazidine.